TNFRSF10B and acute lymphoblastic leukemia: Here, we demonstrate the ability of low-dose RT to upregulate DRs including TRAIL-R2 and Fas cell surface death receptor (FAS) in human ALL NALM6 cells, both in vitro and in vivo.